Drug Trial Radar · NCT04724369
Open-Label Study of 18F-mFBG for Imaging Neuroblastoma
Last checked: Nov 19, 2026Latest source record: Sep 29, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
43
Actual
Start
Nov 18, 2021
Primary completion
Jul 30, 2026
Study completion Aug 30, 2026
Sponsor
- Lead sponsor
- Innervate Radiopharmaceuticals LLC (Formerly: Illumina Radiopharmaceuticals LLC)Industry
- Sponsor type
- Industry
- Collaborators
- New Approaches to Neuroblastoma Therapy Consortium; Memorial Sloan Kettering Cancer Center
- First posted
- Jan 26, 2021
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Diagnostic
- FDA-regulated drug
- Yes
- Who can join
- All sexes
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a Phase 3 study evaluating the positron-emitting radiopharmaceutical 18F-mFBG as an imaging agent for confirming or excluding the presence of neuroblastoma
Conditions
- Neuroblastoma
Interventions
18F-MFBGDrug
Positron-emitting tomography (PET) (either PET/CT or PET/MR) imaging agent
Primary outcomes
What the sponsor says the trial is designed to measure.
- PET Scan Identification of NeuroblastomaTime frame: Imaging at 60 minutes
Locations
8 sites in 1 country. Site status is shown where the registry gives one.
Children's Hospital Los Angeles
Los Angeles, California
University of California, San Francisco
San Francisco, California
Riley Hospital for Children - Indiana University
Indianapolis, Indiana
Dana-Farber Cancer Institute
Boston, Massachusetts
University of Michigan Health System
Ann Arbor, Michigan
Memorial Sloan Kettering Cancer Center
New York, New York
Cincinnati Children's Hospital Medical Center
Cincinnati, Ohio
The Children's Hospital of Philadelphia
Philadelphia, Pennsylvania
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.